A Validation of the 64-Gene Signature Using Affymetrix-HG_U133A Array in Stage I NSCLC From the CALGB Lung Cancer Study (140202)
OBJECTIVES:
- Determine whether the 64-gene signature can accurately predict the prognosis for
survival of patients with stage I non-small cell lung cancer (NSCLC).
OUTLINE: RNA is purified from tissue samples obtained by the CALGB Lung Cancer Study
(CALGB-140202). The RNA samples are used for gene expression analysis using the 64-gene
signature and an Affymetrix-HG_U133A array. Reverse-transcriptase PCR may also be performed
on selected samples.
Observational
N/A
Overall survival, defined as the time from surgery to death of any cause
No
Ming You, MD
Study Chair
Washington University Siteman Cancer Center
United States: Federal Government
CDR0000649826
NCT00990873
July 2009
Name | Location |
---|